Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report

Abstract Pulmonary pleomorphic carcinoma (PPC) is a rare type of non‐small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death‐1 (PD‐1), has been approved as the first‐line...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tae‐Hun Kim, Sun Hyo Park, Ilseon Hwang, Jin Hee Lee, Jin Hee Kim, Hae Won Kim, Hyun Jung Kim
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	PD‐L1 pembrolizumab pulmonary pleomorphic carcinoma Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/1e63e3479feb4021afd93388f480cd72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e63e3479feb4021afd93388f480cd72
record_format	dspace
spelling	oai:doaj.org-article:1e63e3479feb4021afd93388f480cd722021-11-25T13:46:30ZRobust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report2051-338010.1002/rcr2.875https://doaj.org/article/1e63e3479feb4021afd93388f480cd722021-12-01T00:00:00Zhttps://doi.org/10.1002/rcr2.875https://doaj.org/toc/2051-3380Abstract Pulmonary pleomorphic carcinoma (PPC) is a rare type of non‐small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death‐1 (PD‐1), has been approved as the first‐line treatment for advanced NSCLC with robust PD‐L1 expression in at least 50% of tumour cells, without epidermal growth factor receptor gene (EGFR) mutations or anaplastic lymphoma kinase gene (ALK) rearrangement. Here, we report the case of an 81‐year‐old man with multiple comorbidities who was diagnosed with PPC and showed a robust response to pembrolizumab followed by radiation therapy without adverse effects. In the absence of randomized clinical trials for PPCs, our case report demonstrates the potential application of pembrolizumab and radiation therapy for the treatment of PPCs.Tae‐Hun KimSun Hyo ParkIlseon HwangJin Hee LeeJin Hee KimHae Won KimHyun Jung KimWileyarticlePD‐L1pembrolizumabpulmonary pleomorphic carcinomaDiseases of the respiratory systemRC705-779ENRespirology Case Reports, Vol 9, Iss 12, Pp n/a-n/a (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PD‐L1 pembrolizumab pulmonary pleomorphic carcinoma Diseases of the respiratory system RC705-779
spellingShingle	PD‐L1 pembrolizumab pulmonary pleomorphic carcinoma Diseases of the respiratory system RC705-779 Tae‐Hun Kim Sun Hyo Park Ilseon Hwang Jin Hee Lee Jin Hee Kim Hae Won Kim Hyun Jung Kim Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
description	Abstract Pulmonary pleomorphic carcinoma (PPC) is a rare type of non‐small cell lung cancer (NSCLC) with a more aggressive clinical course and a worse outcome than other types of NSCLC. Pembrolizumab, a monoclonal antibody targeting programmed cell death‐1 (PD‐1), has been approved as the first‐line treatment for advanced NSCLC with robust PD‐L1 expression in at least 50% of tumour cells, without epidermal growth factor receptor gene (EGFR) mutations or anaplastic lymphoma kinase gene (ALK) rearrangement. Here, we report the case of an 81‐year‐old man with multiple comorbidities who was diagnosed with PPC and showed a robust response to pembrolizumab followed by radiation therapy without adverse effects. In the absence of randomized clinical trials for PPCs, our case report demonstrates the potential application of pembrolizumab and radiation therapy for the treatment of PPCs.
format	article
author	Tae‐Hun Kim Sun Hyo Park Ilseon Hwang Jin Hee Lee Jin Hee Kim Hae Won Kim Hyun Jung Kim
author_facet	Tae‐Hun Kim Sun Hyo Park Ilseon Hwang Jin Hee Lee Jin Hee Kim Hae Won Kim Hyun Jung Kim
author_sort	Tae‐Hun Kim
title	Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
title_short	Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
title_full	Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
title_fullStr	Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
title_full_unstemmed	Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
title_sort	robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: a case report
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/1e63e3479feb4021afd93388f480cd72
work_keys_str_mv	AT taehunkim robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport AT sunhyopark robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport AT ilseonhwang robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport AT jinheelee robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport AT jinheekim robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport AT haewonkim robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport AT hyunjungkim robustresponseofpulmonarypleomorphiccarcinomatopembrolizumabandsequentialradiotherapyacasereport
_version_	1718413423459434496

Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report

Ejemplares similares